| Drug ID: | Drug82 |
|---|---|
| Drug Name: | Tetomilast |
| CID: | 3025803 |
| DrugBank ID: | DB05298 |
| Modality: | Small Molecule |
| Groups: | investigational |
| US Approved: | NO |
| Other Approved: | NO |
| Identifier: | NCT00092508, , NCT00064454, , NCT00064441, , NCT00317356 |
| Molecular Formula: | C19H18N2O4S |
| Molecular Weight: | 370.4 g/mol |
| Isomeric SMILES: | CCOC1=C(C=C(C=C1)C2=NC(=CS2)C3=NC(=CC=C3)C(=O)O)OCC |
| Synonyms: | Tetomilast; 145739-56-6; Tetomilast [INN]; OPC 6535; 6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid; UNII-S6RXB5KF56; S6RXB5KF56; 2-(3,4-Diethoxyphenyl)-4-(2-carboxy-6-pyridyl)thiazole; 2-Pyridinecarboxylic acid, 6-[2-(3,4-diethoxyphenyl)-4-thiazolyl]-; TETOMILAST [WHO-DD] |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 8 |
| Phase 3: | 5 |
| Phase 4: | 0 |
| Description: | OPC-6535 is a new class of anti-inflammatory agent and phophodiasterase inhibitor. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt695 | 3025803 | Tetomilast | 5142 | PDE4B | Homo sapiens (human) | Inhibitor | |
| dt696 | 3025803 | Tetomilast | 5144 | PDE4D | Homo sapiens (human) | Inhibitor | |
| dt697 | 3025803 | Tetomilast | 5141 | PDE4A | Homo sapiens (human) | Inhibitor | |
| dt698 | 3025803 | Tetomilast | 5143 | PDE4C | Homo sapiens (human) | Inhibitor | |
| dt699 | 3025803 | Tetomilast | 5144 | PDE4D | Homo sapiens (human) | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT00317356 | A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis | PHASE2 | TERMINATED | Otsuka Pharmaceutical Co., Ltd. | Colitis, Ulcerative | DRUG: OPC-6535(Tetomilast) | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
No related literature
You can run management commands to establish drug-literature associations